You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
印尼研究指科兴疫苗对医护保护率达94%
阿思达克 05-12 13:20
中国科兴(SVA.US)疫苗在印尼医护人员实际保护获得理想数据,在防止感染上高度有效。印尼卫生部长Budi Gunadi Sadikin周二(11日)接受《彭博通讯社》访问时称,印尼雅加达2.54万名医护人员在接种第二剂科兴疫苗後被追踪28日,在避免死亡方面保护率达100%,最快七日後避免入院保护率达96%。该批名医护人员被追踪至2月底。

Sadikin亦称,94%医护人员出现免疫效果,该成绩远超疫苗多次临床试验;即使未清楚有关医护人员是否获统一测试以发现无症状感染。Sadikin表示,在入院及死亡个案方面看到非常重大的下降。

科兴发言人指,不能评论印尼情况,直至掌握更多数据。

另科兴首席执行官尹卫东接受该社访问时,为疫苗临床数据差异作辩护,指有更多证据显示在实际环境中科兴表现更佳。尹氏称,智利首批接种人士是长者,仅少於1,500万剂疫苗付运至智利,意味仅700万人可获接种,仅相当於当地1,900万人口的36%。他表示,当地疫情反弹属正常,料源於主要未获接种的年轻人社交活动增加。

尹氏称,在接种了科兴疫苗的智利人当中,89%免受需深切治疗的严重新冠感染。他表示,由於病毒株变异,科兴疫苗在不同地方的保护力料有差异,但疫苗在面对病毒变异上应对显得良好。

被问及疫苗能否防止或阻截病毒传播方面,尹氏称,现时仍未清楚科兴疫苗可否停止或减少在第一环境对病毒曝露敞口,但事实是预防严重感染及死亡更加重要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account